328 related articles for article (PubMed ID: 34386654)
1. Phosphate Balance and CKD-Mineral Bone Disease.
Sprague SM; Martin KJ; Coyne DW
Kidney Int Rep; 2021 Aug; 6(8):2049-2058. PubMed ID: 34386654
[TBL] [Abstract][Full Text] [Related]
2. Phosphate Control: The Next Frontier in Dialysis Cardiovascular Mortality.
McCullough PA
Cardiorenal Med; 2021; 11(3):123-132. PubMed ID: 34120113
[TBL] [Abstract][Full Text] [Related]
3. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
Martin KJ; González EA
Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
[TBL] [Abstract][Full Text] [Related]
4. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
Isakova T; Nickolas TL; Denburg M; Yarlagadda S; Weiner DE; Gutiérrez OM; Bansal V; Rosas SE; Nigwekar S; Yee J; Kramer H
Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764
[TBL] [Abstract][Full Text] [Related]
5. Hyperphosphatemia in Chronic Kidney Disease: The Search for New Treatment Paradigms and the Role of Tenapanor.
Cernaro V; Longhitano E; Casuscelli C; Peritore L; Santoro D
Int J Nephrol Renovasc Dis; 2024; 17():151-161. PubMed ID: 38831770
[TBL] [Abstract][Full Text] [Related]
6. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
[TBL] [Abstract][Full Text] [Related]
7. Phosphate Absorption and Hyperphosphatemia Management in Kidney Disease: A Physiology-Based Review.
Fishbane SN; Nigwekar S
Kidney Med; 2021; 3(6):1057-1064. PubMed ID: 34939015
[TBL] [Abstract][Full Text] [Related]
8. Past, Present, and Future of Phosphate Management.
Doshi SM; Wish JB
Kidney Int Rep; 2022 Apr; 7(4):688-698. PubMed ID: 35497793
[TBL] [Abstract][Full Text] [Related]
9. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
10. An update on tenapanor to treat hyperphosphatemia.
Cianciolo G; Barbuto S; Iacovella F; La Manna G; Galassi A; Ciceri P; Cozzolino M
Drugs Today (Barc); 2022 Jan; 58(1):33-53. PubMed ID: 35107092
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal Inhibition of Sodium-Hydrogen Exchanger 3 Reduces Phosphorus Absorption and Protects against Vascular Calcification in CKD.
Labonté ED; Carreras CW; Leadbetter MR; Kozuka K; Kohler J; Koo-McCoy S; He L; Dy E; Black D; Zhong Z; Langsetmo I; Spencer AG; Bell N; Deshpande D; Navre M; Lewis JG; Jacobs JW; Charmot D
J Am Soc Nephrol; 2015 May; 26(5):1138-49. PubMed ID: 25404658
[TBL] [Abstract][Full Text] [Related]
12. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
13. Small Intestinal Phosphate Absorption: Novel Therapeutic Implications.
Yee J; Rosenbaum D; Jacobs JW; Sprague SM
Am J Nephrol; 2021; 52(7):522-530. PubMed ID: 34515051
[TBL] [Abstract][Full Text] [Related]
14. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
15. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
Moe SM; Radcliffe JS; White KE; Gattone VH; Seifert MF; Chen X; Aldridge B; Chen NX
J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
[TBL] [Abstract][Full Text] [Related]
16. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?
Cozzolino M; Ureña-Torres P; Vervloet MG; Brandenburg V; Bover J; Goldsmith D; Larsson TE; Massy ZA; Mazzaferro S;
Nephrol Dial Transplant; 2014 Oct; 29(10):1815-20. PubMed ID: 24516228
[TBL] [Abstract][Full Text] [Related]
17. Current and Emerging Markers and Tools Used in the Diagnosis and Management of Chronic Kidney Disease-Mineral and Bone Disorder in Non-Dialysis Adult Patients.
Fusaro M; Pereira L; Bover J
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834950
[TBL] [Abstract][Full Text] [Related]
18. EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease-mineral bone disorder.
Tsuboi Y; Ohtomo S; Ichida Y; Hagita H; Ozawa K; Iida M; Nagao S; Ikegami H; Takahashi T; Horiba N
Kidney Int; 2020 Aug; 98(2):343-354. PubMed ID: 32624180
[TBL] [Abstract][Full Text] [Related]
19. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
[TBL] [Abstract][Full Text] [Related]
20. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
